Table 2 Study treatments and outcomes
| Â | Early application | Later application | Odds ratio (95% CI) | p-value |
|---|---|---|---|---|
Mortality | 3/366 (0.8%) | 12/466 (2.6%) | 0.36 (0.08-1.53) | 0.17 |
  Zimbabwe | 1/166 (0.6%) | 1/139 (0.7%) |  |  |
  Zambia | 2/200 (1%) | 11/327 (3.4%) |  |  |
Morbidity | 0/363 (0.0%) | 1/454 (0.2%) | Â | Â |
  Anemic at discharge | 74/321 (23.1%) | 68/322 (26.8%) | 1.10 (0.61 – 1.99) | 0.74 |
  Emergency hysterectomy | 1/210 (0.4%) | 0/295 (0.0%) |  |  |
  Time variables (mean minutes) |  |  |  |  |
  Study entry to death | 282 | 391 |  |  |
  Study entry to shock recoveryα | 165 (90–279) | 209 (114–386) | 1.28 (1.05-1.57)β | 0.015 |
  Study entry to exit | 608.1 | 608.8 |  |  |
  Study entry until NASG | 2.4 | 144.1 |  |  |